AVEIR Leadless Pacemaker (LP) UK Registry

A new generation of pacemakers—small enough to be implanted directly into the heart without wires—is being tracked in a UK-wide registry of 300 patients across 15 hospitals over five years. Why this matters: Standard pacemakers require leads (wires) that run from a chest pocket device to the heart. These leads can break, become infected, or dislodge. Leadless pacemakers, like the AVEIR device, eliminate those risks by sitting entirely inside the heart. But because the AVEIR is the newest approved model, its real-world performance—both during the implant procedure and over years of use—is not yet well documented. The registry collects data on which patients receive it, why clinicians choose it, and how safe and effective it proves in everyday NHS practice. Potential impact: If the registry shows the AVEIR pacemaker is as safe and effective as earlier models, it could become a standard option for patients who need pacing but face higher risks from traditional lead-based devices. This would directly improve care for people with heart conditions that slow or block the heart’s electrical signals, reducing complications and hospital readmissions. The findings will also help NHS hospitals decide which patients benefit most from this technology, shaping procurement and clinical guidelines for years to come.